Supply shortages have unfortunately been an inconvenient problem for years. Currently, the issue is also becoming apparent, for example, in the supply of fever syrup for children. The German Institute for Drug Use Evaluation (DAPI) [Deutsches Arzneiprüfungsinstitut e. V. (DAPI)] has set itself the objective of detecting supply shortages more precisely and more quickly.

As a non-profit institute, the German Institute for Drug Use Evaluation (DAPI) [Deutsches Arzneiprüfungsinstitut e. V. (DAPI)] is constructively involved in the issue of supply shortages - also internationally. Supply problems ought to be detected more quickly and more precisely. The aim is to secure the provision of medicines. In order to make existing and emerging supply shortages more recognisable and manageable for pharmacists, the DAPI has established the method of the so-called digital twin:

• The real object to be mapped

• The digital twin in virtual space

• Information linking the two

Further topics:

• DAPI M - Availability Monitor

  • with availability analysis (diagrams) over the course of the last six months for

    • Ibuprofen 200 mg (Syrup) "fever syrup" and

    • Pantoprazole N3 packs (~100 tablets) 20 mg and 40 mg

• DAPI supports the European supply shortage project MedSRI

• DAPI as licensed partner of SNOMED International

Robust results require support

For reliable results and a high resilience of DAPI M, a high rate of participation by pharmacies is essential.

If a pharmacy software is already connected to DAPI M, the pharmacies concerned have been informed of this by the software company. A pharmacy with linked software can initiate the data delivery to DAPI M by itself by simply ticking the DAPI M option in the software settings. That is all, no additional work beyond that.

If a software house is not yet connected, DAPI will be pleased to provide the software house with comprehensive support in integrating it.

Download the full article: